Besides the natural progestin, progesterone, there are different classes of progestins, such as retroprogesterone (i.e. dydrogesterone), progesterone derivatives (i.e. medrogestone) 17alpha-hydroxyprogesterone derivatives (i.e. chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, megestrol acetate), 19-norprogesterone derivatives (i.e. nomegestrol, promegestone, trimegestone, nesterone), 19-nortestosterone derivatives norethisterone (NET), lynestrenol, levonorgestrel, desogestrel, gestodene, norgestimate, dienogest) and spironolactone derivatives (i.e. drospirenone). Some of the synthetic progestins are prodrugs, which need to be metabolized to become active compounds. Besides the progestogenic effect, which is in common for all progestins, there is a wide range of biological effects, which are different for the various progestins and have to be taken into account, when medical treatment is considered.
PMID 14670641 14670641 DOI 10.1016/j.maturitas.2003.09.014 10.1016/j.maturitas.2003.09.014
Cite this article
Schindler, A. E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J. R., Schweppe, K. W., & Thijssen, J. H. H. (2003). Classification and pharmacology of progestins. *Maturitas*, *46 Suppl 1*, S7-S16. https://doi.org/10.1016/j.maturitas.2003.09.014
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2003;46 Suppl 1:S7-S16. doi:10.1016/j.maturitas.2003.09.014
Schindler, A. E., et al. "Classification and pharmacology of progestins." *Maturitas*, vol. 46 Suppl 1, 2003, pp. S7-S16.
Introduction: Oral contraceptive pills have been implicated in the pathophysiology of breast cancer. Although many studies have examined the relationship between combined oral contraceptives (COCs) an...
Background: The aim of the present study was to investigate the health risks of excess body weight in the light of its protective effects on bone fragility.
Methods: Femoral neck and lumbar spine dua...
Perimenopause/Menopause > Bone Health > BMI and Osteoporosis RiskBone Health > Risk Factors > Weight and Body CompositionPerimenopause/Menopause > Metabolic Health > Obesity Comorbidities
OBJECTIVE: to assess the therapeutic efficacy and safety of oral estriol for the treatment of climacteric symptoms in postmenopausal women.
METHODS: 68 postmenopausal women with climacteric symptoms ...
OBJECTIVE: To determine whether percutaneous estradiol (pE2) (1.5 mg/day) is able to counteract the postmenopausal bone loss in postmenopausal hysterectomized women, in a double-blind study versus ora...
Bone Health > Estrogen Therapy > Postmenopausal Bone PreservationPerimenopause/Menopause > Hormone Therapy > Transdermal EstradiolResearch Methodology > Double-Blind Studies > Bone Density Outcomes